Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
The latest deal over a CD47 asset has got investors wondering who could be next.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
But the company focused on a modified intent-to-treat analysis of its pivotal trial.